Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 16/20 | 0.82 |
| ▸ | KDR | P35968 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 4/20 | 0.63 |
| ▸ | CSF1R | P07333 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234850 | 0.90 | RAF1 (1.00) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL939254 | 0.89 | RAF1 (0.80) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL13946063 | 0.86 | RAF1 (0.64) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL13234879 | 0.85 | RAF1 (0.77) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL13946065 | 0.85 | RAF1 (0.66) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL938059 | 0.84 | RAF1 (0.78) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL14422914 | 0.83 | RAF1 (0.82) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL668459 | 0.83 | RAF1 (1.00) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL4205874 | 0.82 | KDR (0.60) | RAF1KDRRIPK2MAPK13MAPK12 | |
| SCHEMBL13946069 | 0.81 | RAF1 (0.66) | RAF1KDRRIPK2MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885KDR 1151/4885RIPK2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.